3-Keto-5α-abiraterone
From Wikipedia, the free encyclopedia
| Identifiers | |
|---|---|
|
|
| Synonyms | 17-(3-Pyridyl)-5α-androst-16-en-3-one |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C24H31NO |
| Molar mass | 349.518 g/mol |
| 3D model (JSmol) | |
|
|
|
|
3-Keto-5α-abiraterone, also known as 17-(3-pyridyl)-5α-androst-16-en-3-one, is an active metabolite of abiraterone acetate that has been found to possess androgenic activity and to stimulate prostate cancer progression.[1][2] It is formed as follows: abiraterone acetate to abiraterone by esterases; abiraterone to Δ4-abiraterone by 3β-hydroxysteroid dehydrogenase/Δ5-4 isomerase; and Δ4-abiraterone to 3-keto-5α-abiraterone by 5α-reductase.[1][2] 3-Keto-5α-abiraterone may counteract the clinical effectiveness of abiraterone acetate, and so inhibition of its formation using the 5α-reductase inhibitor dutasteride is being investigated as an adjunct to abiraterone acetate in the treatment of prostate cancer.[1][2]
References[edit]
- ^ a b c Li Z, Alyamani M, Li J, Rogacki K, Abazeed M, Upadhyay SK, Balk SP, Taplin ME, Auchus RJ, Sharifi N (May 2016). "Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy". Nature. 533 (7604): 547–51. PMID 27225130. doi:10.1038/nature17954.
- ^ a b c Obst, J. K., & Sadar, M. D. (2016). Directing abiraterone metabolism: balancing the scales between clinical relevance and experimental observation. Translational Cancer Research, 3(5), S529-S531.
 |
This article about a steroid is a stub. You can help Wikipedia by expanding it. |
